Top-Rated StocksTop-RatedNASDAQ:PTGX Protagonist Therapeutics (PTGX) Stock Price, News & Analysis $141.01 +2.58 (+1.86%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Protagonist Therapeutics Stock (NASDAQ:PTGX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PTGX alerts:Sign Up Key Stats Today's Range$137.30▼$142.0050-Day Range$128.75▼$158.6252-Week Range$74.03▼$160.81Volume93,353 shsAverage Volume717,107 shsMarket Capitalization$9.10 billionP/E Ratio136.90Dividend YieldN/APrice Target$158.19Consensus RatingBuy Company Overview Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing peptide-based medicines for immune-mediated and hematologic diseases. The company uses its proprietary peptide technology platform to design therapies intended to act on specific biological pathways and receptors. Its leading program is icotrokinra, also known as JNJ-2113, an oral, targeted inhibitor of the interleukin-23 receptor being developed in collaboration with Janssen Pharmaceuticals for inflammatory and immune-mediated conditions, including psoriasis and inflammatory bowel diseases. Protagonist also developed rusfertide, a hepcidin mimetic peptide designed to regulate iron availability and being studied for polycythemia vera and related hematologic disorders in collaboration with Takeda Pharmaceuticals. Founded in 2006, Protagonist Therapeutics is headquartered in Newark, California. Through strategic collaborations and global clinical development programs, the company’s investigational medicines are being evaluated in markets served by its pharmaceutical partners. Dinesh V. Patel, Ph.D., serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Protagonist Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScorePTGX MarketRank™: 2.189692390715 of 5 starsProtagonist Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 729th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingProtagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.06, and is based on 2 strong buy ratings, 15 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialProtagonist Therapeutics has a consensus price target of $158.19, representing about 14.3% upside from its current price of $138.43.Amount of Analyst CoverageProtagonist Therapeutics has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Protagonist Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings Growth-97.60% Earnings GrowthEarnings for Protagonist Therapeutics are expected to decrease by -97.60% in the coming year, from $4.59 to $0.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protagonist Therapeutics is 134.40, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.79.Price to Earnings Ratio vs. SectorThe P/E ratio of Protagonist Therapeutics is 134.40, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.90.Price to Book Value per Share RatioProtagonist Therapeutics has a P/B Ratio of 14.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Protagonist Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.23% of the float of Protagonist Therapeutics has been sold short.Short Interest Ratio / Days to CoverProtagonist Therapeutics has a short interest ratio ("days to cover") of 11.49, which indicates bearish sentiment.Change versus previous monthShort interest in Protagonist Therapeutics has recently increased by 14.81%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProtagonist Therapeutics does not currently pay a dividend.Dividend GrowthProtagonist Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.59 News SentimentProtagonist Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Protagonist Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for PTGX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows7 people have added Protagonist Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,443,786.00 in company stock.Percentage Held by Insiders5.19% of the stock of Protagonist Therapeutics is held by insiders.Percentage Held by Institutions98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Protagonist Therapeutics' insider trading history. Receive PTGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PTGX Stock News HeadlinesProtagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty CompounderOctober 24 at 12:00 AM | seekingalpha.comComparing Sarepta Therapeutics (NASDAQ:SRPT) and Protagonist Therapeutics (NASDAQ:PTGX)October 19, 2026 | americanbankingnews.com“The crisis that’s emerging now is just the tip of the iceberg,” says Dr. Martin D. Weiss, who has made shocking and accurate predictions for 55 yearsDr. Martin D. Weiss, who predicted the Dot-Com collapse and the failures of Fannie Mae, Bear Stearns, and Lehman Brothers, is warning of a developing financial crisis. The New York Times has credited him as among the first to see the dangers ahead, and Forbes dubbed him Mr. Independence. He says this emerging situation could trigger a chain reaction across banks and markets. Watch his free video breakdown and see the five steps he outlines for investors.October 26 at 1:00 AM | Weiss Ratings (Ad)UBS initiates coverage of Protagonist Therapeutics with buy ratingOctober 12, 2026 | msn.comNektar, Protagonist, Shattuck are Leerink top picks in emerging immunologyOctober 12, 2026 | msn.comUBS Initiates Coverage on Protagonist Therapeutics With Buy Rating, $184 Price TargetOctober 12, 2026 | marketscreener.comMProtagonist Therapeutics (NASDAQ:PTGX) Stock: Insider Asif Ali Sells 58,629 SharesOctober 3, 2026 | insidertrades.comProtagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeptember 9, 2026 | seekingalpha.comSee More Headlines PTGX Stock Analysis - Frequently Asked Questions How have PTGX shares performed this year? Protagonist Therapeutics' stock was trading at $87.34 on January 1st, 2026. Since then, PTGX shares have increased by 58.5% and is now trading at $138.43. How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced its quarterly earnings results on Wednesday, August, 5th. The company reported $2.29 EPS for the quarter, beating the consensus estimate of $2.27 by $0.02. Protagonist Therapeutics's quarterly revenue was up 3746.8% on a year-over-year basis. When did Protagonist Therapeutics IPO? Protagonist Therapeutics (PTGX) raised $90 million in an initial public offering on Wednesday, August 10th 2016. The company issued 7,500,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO. Who are Protagonist Therapeutics' major shareholders? Top institutional investors of Protagonist Therapeutics include State of Alaska Department of Revenue (0.03%), Yousif Capital Management LLC (0.03%), Robeco Institutional Asset Management B.V. (0.02%) and Nisa Investment Advisors LLC (0.01%). Insiders that own company stock include Dinesh V Ph D Patel, Suneel Gupta, Arturo Md Molina, Harold E Selick, Asif Ali, Bryan Giraudo, William D Waddill and Lewis T Williams. View institutional ownership trends. How do I buy shares of Protagonist Therapeutics? Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Protagonist Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Protagonist Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Micron Technology (MU), Block (XYZ), Tesla (TSLA) and Viking Therapeutics (VKTX). Company Calendar Last Earnings8/05/2026Today10/26/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (17m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PTGX's financial health is in the Green zone, according to TradeSmith. PTGX has been in this zone for over 17 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PTGX CIK1377121 Webwww.protagonist-inc.com Phone(510) 474-0170FaxN/AEmployees141Year Founded2006Price Target and Rating Average Price Target for Protagonist Therapeutics$158.19 High Price Target$190.00 Low Price Target$82.00 Potential Upside/Downside+12.2%Consensus RatingBuy Rating Score (0-4)3.06 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)$1.03 Trailing P/E Ratio136.01 Forward P/E Ratio30.71 P/E GrowthN/ANet Income-$130.15 million Net Margins29.40% Pretax Margin29.91% Return on Equity12.03% Return on Assets11.23% Debt Debt-to-Equity RatioN/A Current Ratio21.71 Quick Ratio21.71 Sales & Book Value Annual Sales$46.02 million Price / Sales198.18 Cash FlowN/A Price / Cash FlowN/A Book Value$9.83 per share Price / Book14.34Miscellaneous Outstanding Shares64,710,000Free Float61,350,000Market Cap$9.12 billion OptionableOptionable Beta1.53 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:PTGX) was last updated on 10/26/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredBeginner’s Guide to GoldInflation, trade wars, and market volatility have many savers rethinking how they protect retirement funds. A ...Goldco Direct, LLC | Sponsored$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredReport: OCC clears Trump-linked bankLast month I told investors that a Trump-backed crypto bank could be approved any day. On August 14, it was...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
